Novo Shares Fall Up to 7% as Drugmaker's 2030 Growth Ambitions Disappoint Investors

Novo shares tumbled as much as 7% on Monday after the Danish drugmaker used a Capital Markets Day in London to lay out its strategic ambitions through 2030, a plan that investors judged too modest to close the widening gap with rival Eli Lilly. The stock pared some of its losses but still traded 5.4% lower by midday in Copenhagen, according to CNBC. A separate report from Yahoo Finance put the decline in Novo's New York-listed shares at 6%.

What Novo Actually Announced

Novo said it aims to launch more than five drugs with what it calls "multi-blockbuster" potential by 2030, and to generate more than 150 billion Danish kroner, roughly $23 billion, in risk-adjusted pipeline sales by 2035, including existing assets, per reporting from CNBC and Yahoo Finance. The company also expects compound annual revenue growth between 2026 and 2030 to be in line with a group of industry peers while keeping its adjusted operating margin broadly stable, based on adjusted financial measures, according to Yahoo Finance. That peer group, as identified by Novo and reported by Yahoo Finance, spans Eli Lilly, AstraZeneca, Gilead, Johnson & Johnson, AbbVie, Novartis, Sanofi, Roche, GSK, Amgen, Merck & Co., Biogen, Pfizer and Bristol Myers Squibb.

Novo emphasized that these are strategic ambitions rather than formal financial guidance, using 2026 as a baseline and subject to what the company called inherent uncertainty, Yahoo Finance reported. On research and development, Novo intends to run at least five Phase 3 programs in obesity and diabetes plus at least five additional late-stage programs in other therapeutic areas. The company also plans to expand manufacturing capacity so that ten times as many people with obesity can be treated with oral GLP-1 medicines, targeting more than 60 million patients globally by 2030, according to both Yahoo Finance and CNBC. Novo additionally said it intends to maintain what it describes as an attractive dividend per share, per Yahoo Finance.

The Patent Cliff Behind the Strategy

CEO Mike Doustdar told investors at the event that the "elephant in the room" is that semaglutide, the active ingredient in Wegovy and Ozempic, will begin losing key patent exclusivity in the early 2030s, starting with the U.S. patent expiration in 2032, according to CNBC. The U.S. accounted for more than half of Novo's overall sales last year, CNBC reported. Doustdar said the company intends to emerge from that loss of exclusivity larger and more diversified, telling investors: "We plan to come on the other side of the LOE as a bigger company than we are today and a much more diversified version of it," as quoted by both CNBC and Yahoo Finance.

As part of that shift, Doustdar said Novo will build out its portfolio beyond obesity and diabetes into blood and endocrine disorders, liver disease and cardiovascular disease, and will be more active in business development, which falls outside the 2030 sales target, according to CNBC. That diversification push marks a change from the strategy Doustdar set out after becoming CEO last year, when Novo had sharpened its focus on core obesity and diabetes businesses and moved away from new areas, CNBC noted. The move follows Novo's rebranding from Novo Nordisk to Novo last week alongside a new corporate culture framework, which Doustdar described to CNBC as "parts of the same package" aimed at meeting competition from Lilly.

Analysts Say the Plan Falls Short

Market reaction suggested investors wanted more. Jacob Pedersen of Middelfart Sparekasse told CNBC that benchmarking growth against a broad pharma peer group implies slower growth than markets have historically expected from Novo. "The investors, they are very particular in what they want from Novo, and this doesn't add up to it," Pedersen said, according to CNBC. Per Hansen, savings economist at Nordnet, told Yahoo Finance that investors had hoped for a transformative announcement, adding: "For obvious reasons that miracle does not exist."

The disappointment lands against a backdrop of already soft near-term guidance. In August, Novo said it expects adjusted sales and adjusted operating profit each to be down 6% to flat in 2026 at constant exchange rates, according to both CNBC and Yahoo Finance.

The Widening Gap With Lilly

Heading into Monday's session, Novo shares had fallen 27% over the prior 12 months, while Eli Lilly shares had gained 52% over the same period, CNBC reported. Lilly has captured a majority of the injectable GLP-1 market with Mounjaro and Zepbound despite launching years after Novo's competing drugs, according to CNBC. Read as interpretation rather than forecast, those two figures move in opposite directions over the same 12-month window, illustrating the performance divergence investors were looking for Monday's plan to address.

The market-share data tells a similar story. In the second quarter, Novo held roughly 39% of the obesity drug market against about 61% for Lilly, according to figures reported by Yahoo Finance and attributed to CNBC. That is a 22 percentage point gap by our calculation (39% minus 61%), leaving Novo's share about 36% below Lilly's in relative terms ((39 - 61) / 61 x 100). That backdrop has fed investor concern that Monday's roadmap does not go far enough.

Bottom Line

Novo's 2030 ambitions offer a longer-term diversification story built around new therapeutic areas, expanded manufacturing and pipeline sales targets, but the company itself has framed these as strategic aims rather than guaranteed guidance. With Lilly's share and stock performance far ahead over the past year, investors reacted to Monday's presentation as falling short of the decisive turnaround some had hoped for, sending shares sharply lower even after early losses were pared.